Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes: A Systematic Review and Meta-analysis.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 10 2020
Historique:
pubmed: 9 7 2020
medline: 6 1 2022
entrez: 9 7 2020
Statut: ppublish

Résumé

Whether intervention should be performed in patients with asymptomatic severe aortic stenosis (AS) remains debated. To meta-analyze the natural history of asymptomatic severe AS and examine the association of early intervention with survival. PubMed, Embase, and Cochrane databases were searched from inception to February 1, 2020. Observational studies of adult patients with asymptomatic severe AS. Two investigators independently extracted study and patient characteristics, follow-up time, events, and prognostic indicators of events. Random-effects models were used to derive pooled estimates. The meta-analysis on natural history was performed on the primary end point of all-cause death occurring during a conservative treatment period, with secondary end points consisting of cardiac death, death due to heart failure, sudden death, development of symptoms, development of an indication for aortic valve intervention, and aortic valve intervention. The primary end point for the meta-analysis of early intervention vs a conservative strategy was all-cause death during long-term follow-up. Finally, meta-analysis was performed on the association of prognostic indicators with the composite of death or aortic valve intervention found in multivariable models. A total of 29 studies with 4075 patients with 11 901 years of follow-up were included. Pooled rates per 100 patients per year were 4.8 (95% CI, 3.6-6.4) for all-cause death, 3.0 (95% CI, 2.2-4.1) for cardiac death, 2.0 (95% CI, 1.3-3.1) for death due to heart failure, 1.1 (95% CI, 0.6-2.1) for sudden death, 18.1 (95% CI, 12.8-25.4) for an indication for aortic valve intervention, 18.5 (95% CI, 13.4-25.5) for development of symptoms, and 19.2 (95% CI, 15.5-23.8) for aortic valve intervention. Early intervention was associated with a significant reduction in long-term mortality (hazard ratio, 0.38; 95% CI, 0.25-0.58). Factors associated with worse prognosis were severity of AS, low-flow AS, left ventricular damage, and atherosclerotic risk factors. Data from observational studies and a recent randomized clinical trial suggest that many patients with asymptomatic severe AS develop an indication for aortic valve intervention, and their deaths are mostly cardiac but not only sudden. Other end points besides sudden death should be considered during the decision to perform early intervention that are associated with improved survival.

Identifiants

pubmed: 32639521
pii: 2768167
doi: 10.1001/jamacardio.2020.2497
pmc: PMC7344834
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1112

Auteurs

Brigitta Gahl (B)

Clinical Trial Unit Bern, University of Bern, Bern, Switzerland.

Mevlüt Çelik (M)

Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.

Stuart J Head (SJ)

Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.
Medtronic, Maastricht, the Netherlands.

Jean-Louis Vanoverschelde (JL)

Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
Division of Cardiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Philippe Pibarot (P)

Québec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Michael J Reardon (MJ)

Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas.

Nicolas M van Mieghem (NM)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

A Pieter Kappetein (AP)

Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.

Peter Jüni (P)

Department of Medicine and Institute of Health Policy, Management and Evaluation, Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Bruno R da Costa (BR)

Institute of Health Policy, Management and Evaluation, Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH